Экспрессия опухолеассоциированных генов PRAME, WT1 и XIAP у больных множественной миеломой в процессе интенсивной терапии и аутотрансплантации
Диссертация
В начале 1990;х годов в злокачественно трансформированных гемопоэтических клетках была обнаружена' аномальная экспрессия ряда генов, получивших общее название С/Т (cancer/testis), так как в норме их транскрипция присуща главным образом клеткам семенников. Одним из представителей данного семейства, часто экспрессирующимся при онкогематологических заболеваниях, является ген PRAME, обладающий… Читать ещё >
Список литературы
- Абелев Г. И. механизмы дифференцировки и опухолевый рост//Биохимия.-2000.-С.127−140.
- Абраменко И. В., Белоус Н. И., Мисюрин A.B. Экспрессия гена PRAME при миеломной болезни/ЛГерапевтический архив.- 2004.-Ж7-С.35- 40.
- Андреева Н.Е. Вялотекущая множественная миелома/ЯТроблемы гематологии.-1983.-№ 4.-С.55−58.
- Барлоги Б., Эпстайн Дж., Сельваньягам П., Алексаниан Р. Плазмоклеточная миелома II. Новое в диагностике и лечении заболевания//Гематология и трансфузиология.-1992.-№ 7−8.-С.ЗЗ-39.
- Барышников А.Ю. Программированная клеточная смерть (апоптоз)//Клиническая онкогематология под редакцией! М. А. Волковой.-2001 .-С.34−41.
- Воробьев А.И. Общий патогенез гемобластозов//Руководство по гематологии. Под редакцией академика А.И. Воробьева-2007.-Т.1.-С.147- 150.
- Жеребцова В.А., Сурин B.JL, Менделеева Л. П. Молекулярный мониторинг МРБ при ММ//Проблемы гематологии и переливания крови.-2006.-С.2.
- Козинец Г. И., Мокеева P.A., Касаткина В.В.и соавт. Пролиферация плазматических клеток при множественной миеломеавторадиографическое исследование)//Гематология итрансфузиология.-1986.-Т.31 .-№ 7.-С. 13—17.
- Ю.Кузнецов С. В. Апоптоз и некоторые механизмы его регуляции// Проблемы гематологии.-1998.-№ 2.-С.22−27.
- Татосян A.F., Зуева Э. Ш. Механизмы активации онкогенов// Клиническая гематология под редакцией М. А. Волковой.-2001.-Т. 2.-С.22−28.
- Alt F.W., Oltz Е.М., Young F., et al: VGJ recombination. Immunol. Today 1992- 13: 306−313.
- Anderson K.C. Targeted therapy for multiple myeloma// Semin.Hematol.-2001.-Vol.38.-P.286—294.
- Andrade VC, Vettore A, Felix R ete al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients//Cancer Immunity.-2008.-Vol.8.-P.2−9.
- Attal M., Harousseau J.L., Stoppa A-M. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.//N. Engl. J. Med.-1996.-Vol.335.-P.9r-97.
- Baird P.N., Simmons P.J. Expression-of the Wilms tumor gene (WT1) in normal hemopoiesis//Exp. Hematol.-1997.Vol 25.-P312−320.
- Bakkus M.H., Heirman C., Van Riet Г., et al. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation//Blood.-1992.-Vol.80.-P.2326−2335.
- Bakkus M.H.C., Van-Rirt I. Evidence that the clonogenic cell in multiple myeloma originates from pre-switched but somatically mutated B-cell//Br. J. haematol.-1994.-Vol.87.-P.68−74.
- Barlogie B., Alexanian R., Dicke K.A., et al. High-dose chemoradiotherpy and autologous bone marrow transplantation for resistans multiple myeloma//Blood.-1987.-70.-P.869−872.
- Barl9gie B., Jagannath S., Desican K.R. Total Therapy with Tandem Transplants for Newly Diagnsed Multiple Myeloma/ZBlood.-1999.-93 .-P.55−65.
- Barlogie B., Shaughnessy J., Tricot G., et al. Treatment of multiple myeloma//Blood.-2004.-103.-P.20−32.
- Barragan E., Cervera J., Bolufer P., et al. Prognostic implications of Wilms tumor gene (WT1) expression in-patients with de novo acute myeloid leukemia//Haematologica.-2004.-89.-P.926−933.
- Bataille R., BoccadoroM., Klein B. et al. C-reactive protein and beta2 microglobulin produce a sample and powerful myeloma staging system//Blood.-1992>80.-P.733—737.
- Bataille R., Durie B.G.M., Grenier J. et al. Prognostic factors and' staging in multiple myeloma: A reappraisal//.!. Clin: Oncol.-1986.-4.-P.80−87.
- Bataille R., Durie B.G.M., Grenier J. Serum beta 2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging.//Br. J. Haematol.-1983.-55.-P.439—447.
- Bataille R., Lourdan M., Zhang X. et al. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity plasma cell dyscrasia//J. Clin. Invest.-1984.-84.-P.2008−2011.
- Beauvais D.M., Burbach B.J., Rapraeger AC. The syndecan-1 ectodomain regulates {alpha}v{beta}3 integrin activity in human mammary carcinoma cells.//J. Cell. Biol.-2004.-167.-P. 171−181.
- Bergsagel D.L., Wong О., Bergsagel P.L. Benzene and multiple myeloma: appraisal of scientific evidence/ZBlood.-1999.-94.-1174−1182
- Bernfield M., Gotte M., Park P.W. et al. Functions of cell surface heparan sulfate proteoglycans//Ann. Rev. Biochem.-1999.-68.-P.729−77.
- BGM Durie, J-L Harousseau, JS Miguel et all. Международные единые критерии ответа при множественной миеломе/ZLeukemia!-2006.-20.-Р.1467−1473.
- Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation//Br. J. Haematol.-1998.-l 02.-P.1115−1123.
- Borset M., Hjorth-Hansen H., Seidel C. et al. Hepatocyte growth factor and its receptor c-met in multiple myeloma//Blood.-1996.-88.-P.3998−4004.
- Borset M., Waage A., Brekke O.L., Heiseth E. TNF and IL-6 are. potent growth factors for OH-2, a novel human myeloma cell line.//Eur.J:Haematoh-1994.-53 :-P.31−37.
- Boyapati A., Kanbe E., Zhang D.E. p53 alterations in myeloid leukemia//Acta Haematol:-2004.-111 .-P. 100−106.
- Вгеппе A.-T., Baade Ro Т., Waage A. et ah Interleukin'21 is a growth and survival factor for human myeloma cells//Blood.-2002.-99.-P.3756—3762.
- Burington B, Barlogie В., Zhan F., et al. Tumor cell Gene expression changes following Short-term in vivo exposure to single agent chemotherapeutics are related to survival in Multipal Myeloma//Clin Cancer Res.-2008.-14(15).-P.4821 4829.
- Call K.M., Glaser Т., Ito C.Y., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumor locus//Cell.-1990.-60.-P.509−520.
- Cavo M., Zamagni E., Tosi P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma//Haematologica.-2004.-89.-P.826−831.
- Chen F., Castranova V., Shi X. New insights into the role of Nuclear Factor-KB in cell growth regulation//Am. J. Pathol.- 2001.-159.-P.387−397.
- Chiusa L., Francia de Cell P., Campisi P., et al. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia//Haematologica.-2006.-91 .-P.270−271.
- Condomines M, Hose D, Raynaud P et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis//.! Immunol.-2007.-178.-P3307−3315.
- Creiner J., Ringhoffer M., Simikopinko O., et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia//Exp. Hematol.-2000l-28.-P. 1413−1422.
- D’Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis/ZProc. Natl. Acad. Sci. US A.-1994.-91.-P.4082−4085.
- Dalton W.S. The tumor microenvironment: focus on myeloma//Cancer Treat. Rev.-2003.-29.-P. 11−19.
- Damiano J. S., Cress A. E., Hazlehurst L.A. Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrals and Resistance to
- Apoptosis in Human Myeloma Cell Lines//Blood.-1999.-93.-P. 16 581 667.
- Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma//Blood.-2001 .-98.-P210−216.
- Derksen P.W., Keehnen R.M., Evers L.M. et al. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma//Blood.-2002.-99.-P.1405—1410.
- Desplaniques G, Giuliani N, Dilsignore R et al. Impact of XIAP protein levels on the survival of myeloma cells//Haematologica.-2009.- 94.-P.87−93.
- Deveraux Q.L., Takahashi R., Salvesen G.S., et al. X-linked IAP is a direct inhibitor of cell-death proteases//Nature.-1997.-388.-P.300−304.
- Drach J., Gattringer C., Glassl H. et al. The biological and clinical significance of the Ki-67 growth fraction in multiple myeloma//Hematol. Oncol.-1992.-10.-№ 2.-P. 125−134.
- Durie B.G., Salmon S.E., A clinical stading system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival//Cancer.-1975.-36-P.842−854.
- Durie B.G.M., Stock-Novack D., Salmon S.E. et al. Prognostic value of pretreatment serum beta2 microglobulin in myeloma: A Southwest Oncology Group study//Blood.-1990.-75.-P.823—830.
- Epping M.T., Bernards R. A causal role for the Human tumor antigen prreferntially expressed antigen of Melanoma in cancer//Cancer Res.-2006.-66 (22).-P. 10 639- 10 642.
- Evan G., Liltlewood T. A matter of life and cell death//Science.-1998.-281.-P.1317−1322.
- Fonseca R., Blood E., Rue M., et al. Clinical and biologic implication of recurrent genomic aberration in myeloma//Blood.-2003.-101.-P.4569−4575.
- Fonseca R., Debes-Marun C.S., Picken E.B., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid varian multiple myeloma//Blood.-2003.-102.-P.2562−2567.
- Fu J., Jin Y, Arend L.J. Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis, protein//J. Biol. Chem.-2003.-278.-P. 52 660−52 672.
- Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Kalhs P, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance1 in de novo acute myeloid* leukemia//Leukemia.-1998.-12.-P. 1886−94.
- Gaiger A., Reese V., Disis M.L. et al. Immunity to WT1 in the animal model- and in patients with acute myeloid' leukemia//Blood.-2000.-96(4).-P. 1480−1489.
- Garcia-Gila M., Cabanas C., Garcia- Pardo A. Analysis of the activation state of a4bl integrin in human B cell lines derived from myeloma, leukemia or lymphoma//FEBS Lett.-1997.-418.-P.337−340.
- Gastinne T., Leleu X., Duhamel A. et al. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I//Eur. J. Haematol.-2007.-79.-№ 4-P.297−304.
- Georgii-Hemming P., Wiklund HJ., Ljunggren O., Nilsson K. Insulinlike growth factor I is a growth and. survival factor in human multiple myeloma cell lines//Blood.-1996.-88.-P.2250−2258.
- Goellner S., Steinbach D., Schenk T., et al. Childhood acute myelogenous leukemia: Association between PRAME, apoptosis- and MDR- related gene expression//Eur. J of Cancer.-2006.-42.-P.2807−2814.
- Greaves M.F.//Cancer. Surveys.-1982.-1.-P. 189−204.
- Greipp P.R., Lust J.A., O’Fallon W.M. et al. Plasma cell labeling index and beta2 microglobulin predict survival independent of thymidine-kinase and C-reactive protein in multiple myeloma//Blood:-1993.-81.-P.3382—3387.
- Greipp P.R., Lust J.A., O’Fallon W.M. et al. Plasma cell labeling index and beta2 microglobulin predict survival independent of thymidine-kinase and C-reactive protein=in multiple myeloma//Blood.-1993.-81.-P.3382—3387.
- Guikema J.E.J., Hovenga S., Vellenga E. et- al. GD27 is heterogeneously expressed in multiple myeloma: low CD27 expression^ in patients with high-risk disease//Br. J. Haematol.-2003.-121.-P.36−43.
- Gupta D, Treon S.P., Shima Y. et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications//Leukemia.-2001.-15.-P.1950−1961.
- Haber D.A., Sohn R.L., Buckler A.J., et al. Alternative splicing and genomic structure of the Wilms tumor gene WTl//Proc. Natl. Acad. Sei USA.-1991 .-88.-P.9618−9622.
- Hallek M., Bergsagel P. L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process/ZBlood.-1998.-Vol.91 .-№ 1 .-P.3−21.
- Hatta Y, Takeuchi T, Saitoh T et al. WT1 expression level and clinical factors in multiple myeloma//J Exp Clin Cancer Res.-2005.-24.-P.595−599.
- Heckman C., Mochon E., Arcinas M., et al. The WT1 protein is a negative regulation of the normal bcl-2 allele in t (14−18) lymphomas//J Biol Chem.-1997.-272.-P. 19 609−19 614.
- Hideshima T., Bergsagel P. L, Kuehl W.M. et al. Advances in biology of multiple myeloma: clinical applications//Blood.-2004.-104.-607−618.
- Hideshima T., ChauhanD., Hayashi T. et al. The biological sequelae of stromal' cell-derived factor—1 alpha in multiple myeloma//Mol. Cancer Ther.-2002.-1 .-P.539—544.
- Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional threpy//Blood.-2000.-96.-P.2943−2950.
- Hideshima T., Raje N., Richardson P.G., et al. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma//Ther Clin Risk Manag.-2008.-4(l).-P.129−136.
- Hideshima T., Richardson P. Anderson K.C. Novel therapeutic approaches for multiple myeloma//Immunological Reviews.-2003.-194.-P. 164−176.
- Hjorth-Hansen H., Waage A., Borset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells//Brit. J. Haematol.-1999.-106.-P.28−34.
- Holclic M., Korneluk R. G. X-chromosome-linked Inhibitor of Apoptosis (XIAP)//Nature Reviews Molecular Cell Biology.-2001.-2.-P.550−556.
- Hosen N., Sonoda Y., Oji Y., et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells expression the Wilms tumor gene WT1 at levels similar to those in leukemia cells//Br. J. Haematol.-2002.-116.-P.409−420.
- Hu S., Yang X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO//J. Biol. Chem.-2003.-278.-P. 10 055−10 060.
- Huang Y., Park Y.C., Rich R.L., et al. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain//Cell.-2001 .-104.-P.781−790.
- Humphries M.J. Integrin structure//Biochem. Soc. Trans.-2000.-28,-P.311−339.
- Joazeiro C.A., Weissman A.M. RING finger proteins: mediators of ubiquitin ligase activity//Cell.-2000.-102.-P.549−552.
- Kanavaros P.,. Stefanaki K., Vlachonikolis J: et al. Immunohistochemical expression of the p53, p21waf-l, Rb, pl6 and Ki-67 proteins in multiple myeloma//Anticancer Res.-2000.-20.-N6B.-P.4619—4625.
- Kavano M., Hirano T., Matsuda T. et al. Autocrine generation and essential requirement' of BSF/IL-6 for human multiple myeloma//Nature.-1988.-332.-P.83−85.
- Kawano M.M., Huang N., Harada H. et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas//Blood.-1993.-82.-P.564— 570.
- Klein B., Zhang XG., Jourdan M. et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6//Blood.-l 989.-73.-P.517−526.
- Kool M., van der Linden M., de Haas M., et al. MRP3, an organic anion transporter able to transport anti-cancer drugs//Proc. Natl. Acad. Sci.USA.-1999.-96.-P.6914−6919.
- Kumar S., Rajkumar S.V., Kimlinger T. et al. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlation//Leukaemia.-2005.-19.-N8-P. 1466−1470.
- Kyle R.A., Child J.A., Durie B.G.M. Criteria for the classification of monoclonal gammapathies, multiple myeloma, and related disorders: a report of the international Myeloma Working Group//Br.J.Haematol.-2003.-12 l-P.749−757.
- Kyle R.A., Garton J.P. Spectrum of IgM monoclonal gammopathy in 430 cases//Mayo ClinProc.-1987.-62.-P-719−731.
- Kyle R.A., Gertz M: A., Witzig T. E. et al. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma//Mayo. Clin. Proc.-2003.-78.-P.21−331
- Lee J.S., Scala S., Matsumoto Y., et al. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression//J Cell Biochem.-1997.-65.-P.513−526.
- Leilst M., Jaattela M. Four deaths and funeral: from caspases to alternative mechanisms//Nature Reviews Molecular Cell Biology.-2001.-2.-P.589−598. t
- Leilst M., Jaattela M. Four deaths and funeral: from caspases to alternative mechanisms//Nature Reviews Molecular Cell Biology.-2001.-2.-P.589−598.
- Lu Z.Y., Zhang X.G., Wijdenes J. et al. Interleukin 10 is a growth factor for human myeloma cells//Blood.-1995.-85.-P.2521−2527.
- Luque R., Garcia-Trujillo J.A., Camara C. et al. CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression//Br. J. Haemat.-2002.-l 19.-P.70−78.
- MacFarlane M., Merrison W., Bratton S.B., et al. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro//J. Biol. Chem.-2002.-277.-P.36 611−36 616.
- Malpas J.S., Bergsagel P.L., Kyle R., et al. Myeloma. Biology and management//3-rd Ed. Newcastle.-2004.-P.163−194.
- Mateo G., Castellanos M., Rasillo A. et al. Genetic Abnormalities, and Patterns of Antigenic Expression* in Multiple Myeloma//Clin. Cancer Res.-2005.-ll.-N10-P.3661—3667.
- Matsushita M, Yamazaki R, Ikeda H, Kawakami. Y. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and" — therapeutic methods for hematological-malignancies//Leuk Lymph.-2003 .-44.-3 .-P:439−444.
- Matsushita M., Yamazaki R., Ikeda H. et al. Preferentally expressed antigen of Melanoma (PRAME) in the development of diagnostic and therapeutic metods for hematological malignancies//Leukemia&Lymphoma.-2003.-44.-3 .-P.439−444.
- McElwan T.J., Powles R.L. High-dose intravenous melphalan for plasma-cell leukemia and myeloma//Lancet.-1983.-l.-P.822−824.
- Michigami T., Shimizu N., Williams P.J. et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and a (4)b (l)-integrin enhances production of osteoclast—stimulating activity//Blood.-2000.-96.-P. 1953—1960.
- Miller, L.K. An exegesis of LAPs: salvation and’surprises from BIR motifs//Trends Cell. Biol.-1999.-9.-P.323−328.
- Mitsiades CS, Mitsiades N, Poulaki V et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications//(c)ncogene.-2002.-21.-P.5673−83.
- Moehler T.M., Neben K., Ho A.D., Goldschmidt H. Angiogenesis in hematologic malignancies//Ann. Hematol.-2001.-80.-P.695−705.
- Moreau P., Robillard N., Avet-Loiseau H. et al. Patients with GD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma//Haematologica.-2004.-89.-P.547—551.
- Nakagawa Y, Abe S, Kurata M et al. IAP family protein expression correlates with poor outcome of multiple5 myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes//Am J Hematol.-2006.-81.-P.824−83k
- Nakatani K., Sakane H., Thompson DA., et al. Identification of a human AKT3 (protein kinase b gamma) which contains the regulatory serine phosphorylation site//Biochem Biophys Res Commun.-1999.-257.-P.906−910.
- Nicholson, D.W. Apoptosis. Baiting death inhibitors//Nature.-2001.-410.-P.33−34.
- Norfolk D.} Child J.A., Cooper E.H. et al. Serum beta 2 microglobulin in myelomatosis: Potential value in stratification and monitoring//Br. J. Cancer.-1979.-39.-P.510−515.
- Oh Y., Gucev Z., Ng L., Muller H.L., Rosenfeld R.G. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells//Prog. Grow. Fact. Res.-1995.-6.-P.503—512.
- Ong Y.L., McMullin M.F., Bailie KEM, et al. High bax expression is a good prognostic indicator in acute myeloid leukemia//Br. J Haematol.-2000.-111 .-P. 182−189.
- Perez-Simon J., A., Garcia-Sanz R., Tabernere M.D., et al. Prognostic value of numerical chromosomal aberrations in multiple myeloma: a FISH analysis of 15 different chromosoms//Blood.-1998.~91.-P.3366−3371.
- Proto-Siqueira R., Figueiredo- Pontes. L.L., Panepucci R.A. et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphoid leukemia and mantle cell lymphoma/ZLeukemia Research.-2006.-30.-P. 1333−1339.
- Qin Y, Zhu H, Jiang B et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease//LeukResearch.-2009.-33.-P.384−390.
- Rajkumar S.V., Leong .T, Roche P.C., et al. Prognostic value of bone marrow angiogenesis in multiple myeloma//Clin. Cancer Res.-2000.-6.-P.3111−3116.
- Rapraeger A.C. The coordinated regulation of heparan sulfate, syndecans and cell behavior//Curr. Opin. Cell Biol.-1993.-5.-P.844−853.
- Rawstron A., Barrans S., Blythe D. et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression//Br. J. Haematol.-1999.-104.-P. 138−143.
- Reiman T., Seeberger K., Taylor B.J., et al. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone//Blood.-2001.-98.-P.2791−2740.
- Richardson P. G., Blood E., Mitsiades C. S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma//Blood.-2006.-108.-10.-P.3458−3464.
- Ridley R.C., Xiao H., Hata H. et al. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen/ZBlood.-1993 .-81 .-P.767−774.
- Riedel D.A., Pottern L.M. The epidemiology of, multiple myeloma//Hematol Oncol Clin North Am.-1992.-6.-P.225−247.
- Rivera M.N., Haber D.A. Wilms tumor: connecting tumorogenesis and organ development in the kidney//Nat. Rev. Cancer.-2005.-5.-P.699−712.
- Ross D.D. Novel mechanisms of drug resistance in leukemia//Leukemia:-2002.-14.-P.467−473.
- Ross D.D., Yang W., Abruzzo L.V., et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNAexpression in mitoxantrone-selected cell lines//J Natl. Cancer Inst.1999.-91.-P.429−433.
- Saatchi C, Caglayan A, Kocyigit I et al. Expression of WT1 gene in multiple myeloma patients at diagnosis: is WT1 gene expression a useful marker in multiple myeloma//Hematology.-2010.-Vol.l5.-Nl.-P.39−41.
- Sahota S.S., Garand R., Mahroof R. et al. V (H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events//Blood.-1999.-Vol.94.-P. 1070−1146.
- San Miguel J.F., Garcia-Sanz R., Gonzalez M. et al: A new staging system for multiple myeloma based on the number of S-phase plasma cells//Blood.-1995.-85.-P.448—455.
- Sanz—Rodriguez F., Hidalgo A., Teixido J. Chemokine stromal cell-derived factor-la modulates VLA-4 integrin-mediated multiple myeloma cell1 adhesion to CS-l/fibronectin and VCAM-l//Blood.-2001 .-97.-P.346−351.
- Schlessinger J., Plotnikov A.N., Ibrahimi O.A. et al: Crystal structure of a ternary FGF—FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization//Mol. Cell Endocrinol.2000.-6:-P.743—750:
- Schwartz M.A., Ginsberg M.H. Networks and crosstalk: integrin signaling spreads//Nat. Cell. Biol.-2002.-4.-E65-E68.
- Sezer O., Niemoller K., Eucker J. et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma//Ann. Hematol.-2000.-79.-P.574—577.
- Shain K.H., Landowski T.H., Dalton W.S. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance//Curr. Opin. 0ncol.-2000.-12.-P.557−563.
- Shou Y., Martelli M.L., Gabrea A., et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma//Proc. Natl. acad. Sci. USA.-2000.-97.-P.228−233.
- Silke J., Ekert P.G., Day C.L. et al. Direct inhibitor of caspase 3 is dispensable for the anti-apoptotic activity of XEAP//The EMBO Jornal.-2001.-20.-12.-P.3114−3123.
- Singhal S., Mehta J., Desikan R. et al. Antitumor activity of thalidomide in refractory multiple myeloma//N. Engl. J. Med.-1999.-341.-P.1565−1571.
- Smadja N.V., Bastard C., Brigaudeau C., et al. Hypodiploidy is a major prognostic factor in. multiple myeloma//Blood.-2001.-98.-P.2229−2238.
- Srinivasula S.M., Hedge R., Saleh A., et al. A conserved XIAP-interaction< motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis//Nature.-2001 .-410.-P. 112−116.
- Sun Y. E 3 Ubiquitine ligases as Cancer Targets and Biomarkers//Neoplasia.-2006.-8.-P.645−654.
- Tai Y.T., Podar K., Catley L. et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of bl—integrin and phosphatidilinositol 3'-kinase/AKT signaling//Cancer Res.-2003.-63.-P.5850−5858.
- Tamm I., Kornblau S.M., Segall H., et al. Expression-and prognostic Significance of IAP- Family genes in Human Cancer and Myeloid Leukemias//Clin. Cancer Res.-2000.-6.-P.1796−1803.
- Tanaka Y., Kimata K., Adams D. H-, Eto S. Modulation of cytokine function by heparan sulfate proteoglycans: sophisticated models for the regulation of cellular responses to cytokines//Proc. Assoc. Am. Physicians.-1998.-110.-P.118- 125.
- Valeria C. C. Andrade, Vettore A. L., et al. Prognostic impact of cancer/testis antigen expression in advanced' stage multiple myeloma patients//Cancer Immunity.-2008.-8.-P.2−10.
- Vescio R.A., Cao J., Hong C. H: et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity//.!. Immunol.-1995.-Vol.155.-P.2487−2497.
- Vivanco I., Sawyers C.L. The phosphatidilinositol 3-kinase — Akt pathway in human cancer. Nature reviews: cancer. 2002- 2: 489−501
- Watari K., Tojo A., Nagamura-Inoue T., et al. Indefication of a melanoma antigen, PRAME, as a BCR/ABL inducible gene//FEBS Lett.-2000.-466.-P.367−371.
- Wijdenes J., Vooijs W.C., Clement C. et al. A plasmacyte selective monoclonal antibody (B-B4) recognizes syndecan-l//Br. J. Haematol.-1996.-94.-P.318−323.
- Xu J.L., Lai R., Kinoshita T. et al. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade//J. Clin. Pathol.-2002.-55.-P.530−534.
- Yaccoby S., Barlogie B., Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations//Blood.-1998.-92.-P.2908−2913.
- Yang L., Han Y, Saiz F.S. et al. A tumor suppressor and oncogene: the WT1 story//Leucemia.-2007.-21.-P.868−876.
- Yang, Y, and Yu, X. Regulation of apoptosis: the ubiquitous way//FASEB J.-2003.-17.-P.790−799.